December 19, 2006 10:30 AM Eastern Time
DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/reports/c47292) has announced the addition of Espicom Business Intelligence’s CNS Drug Discoveries: Multiple Sclerosis Chapter to their offering.
The incidence of multiple sclerosis varies throughout the world, although there is a significantly higher incidence of the disease found in the Northern Hemisphere. Find out more in this chapter of CNS Drug Discoveries.
It is estimated that over 350,000 Americans (approximately 1 in 1,000 aged over 30 years) live with multiple sclerosis (MS) and approximately 3 million live with it worldwide. However, the prevalence may be higher because of the uncertainty in diagnosing the condition. Women are twice as susceptible as men and it is more common in people in northern latitudes over the age of 18 years. In addition, siblings of an individual with multiple sclerosis have a higher chance of developing the disease.
The incidence of multiple sclerosis varies throughout the world, although there is a significantly higher incidence of the disease found in the northern hemisphere. Multiple sclerosis is the most common cause of neurological disability in young adults in the UK.
It is variable in presentation and progression. Although there is no cure, there are many symptomatic treatments available. However, many patients do not respond to currently available products (30%) and the more chronic forms (secondary-progressive MS) are poorly treated with existing therapies.
Global multiple sclerosis market
The MS market is estimated to be worth US$4.9 billion in 2006 with a growth rate of 8.9% year-on-year. It is the fifth largest segment of the CNS market and has attracted considerable R&D investment from big pharma, biotechnology companies and specialty pharma. The market is currently driven by the use of six disease-modifying agents: Avonex (Biogen Idec), Betaseron/Betaferon (Schering AG), Copaxone (Teva), Novatrone (Schering AG), Rebif (Serono/Pfizer) and Tysabri (Biogen Idec/Elan).
Sales growth will be driven by current drugs gaining broader indications, MS medicine being prescribed earlier in treatment in clinically-defined multiple sclerosis patients and the longer-term use of combination therapies as more classes of drug become available.
Key questions answered in this chapter include:
-What are the 5 leading products in the US, Europe and Japan?
-What will the shape of the market be in 2012?
-How will Biogen Idec defend its market leading position from Serono, Schering AG and Teva?
-What role will combination therapies play?
-What opportunities are there in the treatment of primary-progressive multiple sclerosis?
-What are the prospects for drugs in development such as Campath, Mylinax, and laquinimod?
Content Outline:
MULTIPLE SCLEROSIS
EXECUTIVE SUMMARY
THE FACTS
PATIENT STATISTICS
PATIENT MODEL
DRUG GROWTH DRIVERS
DRUG GROWTH RISKS/DAMPENERS
GLOBAL MS MARKET
GLOBAL SALES SPLIT
CURRENT TREATMENTS
ANALYSIS OF LEADING BRANDS
Disease-modifying agents
GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005–2012
NEW DRUGS IN R&D
ANALYSIS OF PHASE III DRUGS
MS Symptoms
GLOBAL SALES FORECASTS OF PHASE III MS DRUGS 2006–2012
ANALYSIS OF PHASE II DRUGS
Disease-modifying agents
Vaccines
GLOBAL SALES FORECASTS OF PHASE II MS DRUGS 2006 – 2012
COMPETITOR RATIO ANALYSIS - PRODUCTS
COMPETITOR RATIO ANALYSIS - COMPANIES
DISCONTINUATION OF DRUGS
MS APPENDIX 1
MS APPENDIX 2
MS APPENDIX 3
MS APPENDIX 4
MS APPENDIX 5
Ms APPENDIX 6
MS GLOSSARY
MS REFERENCES
ACRONYMNS
For more information visit http://www.researchandmarkets.com/reports/c47292
Contacts
Research and Markets
Laura Wood
Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com
